EPISODE · Dec 4, 2019 · 32 MIN
Adjuvant Therapy in Renal Cell Carcinoma
from AUAUniversity · host American Urological Association
Co-Host: Alexander Kutikov, MD, FACS At the conclusion of these activities, participants will be able to: 1. Discuss the evolving landscape of adjuvant therapy for the treatment of RCC. 2. Identify best practices for risk assessment and patient selection for adjuvant RCC therapy. 3. Differentiate the roles of urologist and medical oncologist in the care of patients with RCC. CME Available: auau.auanet.org/node/26087 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
What this episode covers
Co-Host: Alexander Kutikov, MD, FACS At the conclusion of these activities, participants will be able to: 1. Discuss the evolving landscape of adjuvant therapy for the treatment of RCC. 2. Identify best practices for risk assessment and patient selection for adjuvant RCC therapy. 3. Differentiate the roles of urologist and medical oncologist in the care of patients with RCC. CME Available: auau.auanet.org/node/26087 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
NOW PLAYING
Adjuvant Therapy in Renal Cell Carcinoma
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.